Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) [Online Tables] Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holbrook, A. M. Articles by King, D. Search for Related Content PubMed PubMed Citation Articles by Holbrook, A. M. Articles by King, D. Related Collections Drugs: psychiatry Other evidence-based medicine Sleep disorders

Meta-analysis of benzodiazepine use in the treatment of insomnia

From the Centre for Evaluation of Medicines, St. Joseph's Hospital and McMaster University, Hamilton, Ont.

Abstract

Objective: To systematically review the benefits and risks associated with the use of benzodiazepines to treat insomnia in adults.

Data sources: MEDLINE and the Cochrane Controlled Trials Registry were searched for English-language articles published from 1966 to December 1998 that described randomized controlled trials of benzodiazepines for the treatment of insomnia. Key words included "benzodiazepines" (exploded), "randomized controlled trial" and "insomnia." Bibliographies of relevant articles were reviewed for additional studies and manufacturers of benzodiazepines were asked to submit additional randomized controlled trial reports not in the literature.

Study selection: Articles were considered for the meta-analysis if they were randomized controlled trials involving patients with insomnia and compared a benzodiazepine with placebo or another active agent. Of the 89 trials originally identified, 45 met our criteria, representing a total of 2672 patients.

Data extraction: Data were extracted regarding the participants, the setting, details of the intervention, the outcomes (including adverse effects) and the methodologic quality of the studies.

Data synthesis: The meta-analyses of sleep records indicated that, when compared with placebo, benzodiazepines decreased sleep latency by 4.2 minutes (non-significant; 95% confidence interval [CI] -0.7 to 9.2) and significantly increased total sleep duration by 61.8 minutes (95% CI 37.4 to 86.2). Patient-reported outcomes were more optimistic for sleep latency; those randomized to benzodiazepine treatment estimated a sleep latency decrease of 14.3 minutes (95% CI 10.6 to 18.0). Although more patients receiving benzodiazepine treatment reported adverse effects, especially daytime drowsiness and dizziness or light-headedness (common odds ratio 1.8, 95% CI 1.4 to 2.4), dropout rates for the benzodiazepine and placebo groups were similar. Cognitive function decline including memory impairment was reported in several of the studies. Zopiclone was not found to be superior to benzodiazepines on any of the outcome measures examined.

Interpretation: The use of benzodiazepines in the treatment of insomnia is associated with an increase in sleep duration, but this is countered by a number of adverse effects. Additional studies evaluating the efficacy of nonpharmacological interventions would be valuable.

This article has been cited by other articles:

				S. Passarella and M.-T. Duong Diagnosis and treatment of insomnia Am. J. Health Syst. Pharm., May 15, 2008; 65(10): 927 - 934. [Abstract] [Full Text] [PDF]

				N. Cimolai Response Can Fam Physician, March 1, 2008; 54(3): 348 - 351. [Full Text] [PDF]

				K. A. Hecksel, J. M. Bostwick, T. M. Jaeger, and S. S. Cha Inappropriate Use of Symptom-Triggered Therapy for Alcohol Withdrawal in the General Hospital Mayo Clin. Proc., March 1, 2008; 83(3): 274 - 279. [Abstract] [Full Text] [PDF]

				D. J. Greenblatt, J. S. Harmatz, and A. Karim Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2 J. Clin. Pharmacol., April 1, 2007; 47(4): 485 - 496. [Abstract] [Full Text] [PDF]

				K. M. Simpson, K. C. Richards, C. A. Enderlin, P. S. O'Sullivan, and M. Koehn Medications and Sleep in Nursing Home Residents With Dementia Journal of the American Psychiatric Nurses Association, October 1, 2006; 12(5): 279 - 285. [Abstract] [PDF]

				J. Glass, K. L Lanctot, N. Herrmann, B. A Sproule, and U. E Busto Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, November 19, 2005; 331(7526): 1169. [Abstract] [Full Text] [PDF]

				J. Stebbing, L. Waters, L. Davies, S. Mandalia, M. Nelson, B. Gazzard, and M. Bower Incidence of Cancer in Individuals Receiving Chronic Zopiclone or Eszopiclone Requires Prospective Study J. Clin. Oncol., November 1, 2005; 23(31): 8134 - 8136. [Full Text] [PDF]

				D. J. Buysse, A. Germain, D. Moul, and E. A. Nofzinger Insomnia Focus, October 1, 2005; 3(4): 568 - 584. [Full Text] [PDF]

				M. H. Silber Chronic Insomnia N. Engl. J. Med., August 25, 2005; 353(8): 803 - 810. [Full Text] [PDF]

				R. M. Benca Diagnosis and Treatment of Chronic Insomnia: A Review Psychiatr Serv, March 1, 2005; 56(3): 332 - 343. [Abstract] [Full Text] [PDF]

				What's wrong with prescribing hypnotics? DTB, December 1, 2004; 42(12): 89 - 93. [Abstract] [Full Text] [PDF]

				M.-C. Ouellet, J. Savard, and C. M. Morin Book Review: Insomnia following Traumatic Brain Injury: A Review Neurorehabil Neural Repair, December 1, 2004; 18(4): 187 - 198. [Abstract] [PDF]

				A. M Holbrook Treating insomnia BMJ, November 20, 2004; 329(7476): 1198 - 1199. [Full Text] [PDF]

				T. A Furukawa Withdrawal of benzodiazepines in elderly long term users does not produce significant adverse effects in the short term Evid. Based Ment. Health, May 1, 2004; 7(2): 46 - 46. [Full Text] [PDF]

				R. D. Jindal, D. J. Buysse, and M. E. Thase Maintenance Treatment of Insomnia: What Can We Learn From the Depression Literature? Am J Psychiatry, January 1, 2004; 161(1): 19 - 24. [Abstract] [Full Text]

				N. J.G. Pimlott, J. E. Hux, L. M. Wilson, M. Kahan, C. Li, and W. W. Rosser Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial Can. Med. Assoc. J., April 1, 2003; 168(7): 835 - 839. [Abstract] [Full Text] [PDF]

				M. T. Smith, M. L. Perlis, A. Park, M. S. Smith, J. Pennington, D. E. Giles, and D. J. Buysse Comparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia Am J Psychiatry, January 1, 2002; 159(1): 5 - 11. [Abstract] [Full Text] [PDF]

				M. Z. Goldstein Practical Geriatrics: Insomnia in Late Life Psychiatr Serv, December 1, 2001; 52(12): 1573 - 1575. [Full Text] [PDF]

				J. Savard and C. M. Morin Insomnia in the Context of Cancer: A Review of a Neglected Problem J. Clin. Oncol., February 1, 2001; 19(3): 895 - 908. [Abstract] [Full Text] [PDF]

				J. Montplaisir Treatment of primary insomnia Can. Med. Assoc. J., August 1, 2000; 163(4): 389 - 390. [Full Text] [PDF]

				A. Holbrook and R. Labiris Treatment of primary insomnia Can. Med. Assoc. J., August 1, 2000; 163(4): 390 - 391. [Full Text] [PDF]

				T. Furukawa Review: benzodiazepines increase sleep duration but also lead to adverse effects in adults with insomnia Evid. Based Ment. Health, August 1, 2000; 3(3): 81 - 81. [Full Text]

				A. M. Holbrook, R. Crowther, A. Lotter, C. Cheng, and D. King The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach Can. Med. Assoc. J., January 1, 2000; 162(2): 216 - 210. [Abstract] [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2000, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.